# Obinutuzumab in Primary MN

> **NCT05050214** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 20 (actual)

## Conditions studied

- Membranous Nephropathy

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT05050214
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-18
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050214, "Obinutuzumab in Primary MN". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05050214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*